SORIATANE (acitretin), retinoid

Improve compliance with the measures for prescribing and dispensing in women of childbearing potential to prevent pregnancy under treatment and for 2 years after discontinuation. 

• SORIATANE has Marketing Authorisation in the treatment of psoriasis, severe keratinisation disorders and severe forms of lichen planus.
• Pregnancies have occurred under treatment due to lack of compliance with the prescribing and dispensing conditions.
• The role of SORIATANE in the therapeutic strategy has not changed, but the teratogenic risk and the restrictions imposed on women of childbearing potential, up to 2 years after the last dose, must be considered in the choice of this medicinal product.